XML 46 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue
6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue

5. Revenue

 

We generate revenue primarily through the sales of our licensed products Ameluz®, BF-RhodoLED® lamps and Xepi®. Revenue from the sales of our BF-RhodoLED® lamp and Xepi® are relatively insignificant compared with the revenues generated through our sales of Ameluz®.

 

Related party revenue relates to an agreement with Biofrontera Bioscience GmbH (“Bioscience”) for BF-RhodoLED® leasing and installation service. Refer to Note 13, Related Party Transactions.

 

An analysis of the changes in product revenue allowances and reserves is summarized as follows:

 

(in thousands):  Returns   Co-pay assistance program   Prompt pay discounts   Government and payor rebates   Total 
Balance at December 31, 2021  $43   $101   $48   $54   $246 
Provision related to current period sales   5    380    11    129    525 
Credit or payments made during the period   (5)   (300)   (20)   (115)   (440)
Balance at June 30, 2022  $43   $181   $39   $68   $331 
                          
Balance at December 31, 2022  $48   $9   $5   $20   $82 
                          
Provision related to current period sales   3    62    3    134    202 
Credit or payments made during the period   -    (71)   (2)   (59)   (132)
Balance at June 30, 2023  $51    -    6    95    152